

4 September 2024

ASX Release

Notice under Section 708A of the Corporations Act

This notice is given by **Firebrick Pharma Limited** (Issuer or Company) (ASX:FRE) under section 708A(5)(e) of the Corporations Act 2001 (Cth) ("Act").

The Company has today issued 360,000 ordinary fully paid shares upon the exercise of unlisted options at an exercise price of \$0.0067 per ordinary fully paid share ("**Issued Shares**")

In accordance with section 708A(5)(e) of the Act, the Company gives notice that:

1. the Issued Shares were issued without disclosure to investors under Part 6D.2 of the Act;
2. as at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Act, as they apply to the Company and sections 674 and 674A of the Act; and
3. as at the date of this notice the Company has submitted an application to a relevant health authority for the approval of Nasodine Nasal Spray for marketing as a nasal antiseptic in an international market but is not in a position to name the specific country. Until the agency has confirmed that the application has passed validation and been accepted for evaluation, the Company is not in a position to provide more details. Whether the application will be accepted for evaluation is unknown and as is the likely date for any confirmation of its acceptance. There is no further information that is 'excluded' information within the meanings of section 708A(7) and 708A(8) of the Act, being information:
 - a) that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules;
 - b) that investors and their professional advisers would reasonably require for the purposes of making and informed assessment of:
 - i. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
 - ii. the rights and liabilities attaching to the Securities.

This announcement has been authorised for release by the Board of Firebrick Pharma Limited.

Yours faithfully



Stephen Buckley

Company Secretary

About Firebrick Pharma

Firebrick Pharma is a pharmaceutical innovator focused on developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). The Company has successfully developed a PVP-I nasal spray (Nasodine® Nasal Spray) and filed international trademarks and multiple patents on the product. The Company has also completed six clinical trials that have affirmed the product's safety and generally supported its efficacy as an antimicrobial nasal spray with utility in a range of clinical settings. Firebrick is now commercialising Nasodine in international markets, with the product already launched in the United States and Singapore.

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com